Halozyme Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2009 | -845.4% | -845.4% | — |
| FY2010 | -261.6% | -261.6% | -58.3% |
| FY2011 | -181.4% | -181.4% | -30.1% |
| FY2012 | -109.6% | -68.2% | -39.7% |
| FY2013 | 417.6% | -280.3% | -82.0% |
| FY2014 | -165.3% | -75.0% | -41.2% |
| FY2015 | -75.0% | -45.4% | -17.7% |
| FY2016 | 317.2% | -61.8% | -39.4% |
| FY2017 | 30.2% | 18.9% | 12.1% |
| FY2018 | -32.3% | -28.3% | -18.2% |
| FY2019 | -78.7% | -15.2% | -12.8% |
| FY2020 | 85.5% | 85.5% | 22.3% |
| FY2021 | 204.5% | 40.9% | 36.5% |
| FY2022 | 119.0% | 12.2% | 11.0% |
| FY2023 | 336.0% | 17.8% | 16.2% |
| FY2024 | 122.1% | 23.8% | 21.5% |
| FY2025 | 649.2% | 14.5% | 12.5% |